Navigation Links
Penn research offers road map to safer pain control, cost savings during colonoscopies
Date:3/11/2008

(PHILADELPHIA) At a time when several U.S. health insurers have discontinued payment for use of the sedative propofol during most screening colonoscopies, physicians at the University of Pennsylvania School of Medicine have discovered that an alternative way to administer the drug could both save millions of health care dollars and provide a safer way to deliver optimal pain relief.

The researchers studied two groups of patients who received patient-controlled sedation administered themselves with the push of a button during their colonoscopy. One group received a combination of the sedatives propofol and remifentanil, while the other received the drugs midazolam and fentanyl. Those in the propofol arm took only about half as long to be sedated, were able to walk quicker after the procedure, and spent much less time in the recovery room.

The findings, published in the February issue of the journal Anesthesia and Analgesia, shed additional light on Aetna, Humana and other large health insurers recent decisions to discontinue payment for the use of the sedative propofol during most routine colonoscopies, because it generally requires an anesthesiologist to be present to monitor for adverse reactions during the procedure. Their involvement adds several hundred dollars to the cost of the procedure, but without insurance coverage for this popular pain relief choice, physicians worry that more patients will avoid the lifesaving test, which detects and removes pre-cancerous polyps. Last year, 55,000 Americans died of colorectal cancer, making it the nations second-leading cancer killer.

Compliance with screening regimens will save lives at a rate several orders of magnitude greater than the number of lives lost to sedation, says Jeff E. Mandel, MD, MS, clinical associate professor Anesthesiology and Critical Care at Penn. As physicians, we should look for ways to find the optimal balance between access to care and risks. No ones interest is served by fewer patients having access to safe, painless colonoscopy.

Previous studies showed propofol helps patients relax quicker, and that can be associated with a more thorough exam. The Penn researchers say that blending patient-controlled IV propofol and remifentanil with continuous monitoring by an anesthesiologist similar to the way in which the doctors keep tabs on patients receiving epidural pain relief during labor and following many surgeries -- would provide patients with an ideal mix of pain relief and care from a trained anesthesiologist.

Since the researchers found that patients in the studys propofol/remifentanil arm were able to walk unassisted sooner after their procedure than those who received midazolam and fentanyl for sedation, the research also points to ways to reduce staffing in hospitals postanesthesia care units a major cost savings to third-party payers.

Any solution that ignores economic realities is doomed to failure, says Dr. Mandel. But no solution that ignores the best interest of patients is likely to succeed.


'/>"/>

Contact: Holly Auer
holly.auer@uphs.upenn.edu
215-200-2313
University of Pennsylvania School of Medicine
Source:Eurekalert

Related medicine news :

1. Leading researchers honored for progress in cancer prevention, detection and treatment
2. WaferGen Launches SmartSlide 200 Micro-Incubation System for Stem Cell Research and Cell Biology Applications
3. Wasserman Morris Initiates Research Coverage on Crdentia
4. Research shows promise for potential new gene therapy strategy for muscle-wasting diseases
5. Mayo Clinic proceedings highlights research about cardiovascular benefits of omega-3 fatty acids
6. University of Pittsburgh researchers crack code of 3-D structure in key metabolic protein
7. UCF researchers discover a new protein family implicated in inflammatory diseases
8. Size does matter: Researchers adapt drug dosing to body size
9. Genetic research unveils common origins for distinct clinical diagnoses
10. Burroughs Wellcome Fund grants $9.75 million towards translational researchers
11. Researchers Design Promising Cancer Drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... Raleigh, NC (PRWEB) , ... December 02, 2016 , ... ... the Open Enrollment Period (or Annual Election Period), is ending December 7th. Currently-enrolled Medicare ... plan (Part C) or prescription drug plan (Part D) need to make changes during ...
(Date:12/2/2016)... New York, NY (PRWEB) , ... December 02, ... ... today, featuring an inspirational interview of two ostomy patients, standing as living proof ... million people suffer from digestive diseases and issues that spike around the holidays. ...
(Date:12/2/2016)... ... December 02, 2016 , ... Mediaplanet ... in USA Today, which covers the innovative treatments, therapeutic technologies, and revolutionized nutrition ... lives. “We are prolonging life 6 years in the last 3 decades,” says ...
(Date:12/2/2016)... ... 02, 2016 , ... Universal Medical Systems, Inc. (UMS) the ... company to offer robotic imaging to veterinary medicine is sponsoring the appearance of ... the American Association of Equine Practitioners 62nd Annual Convention from December 4-6, 2016 ...
(Date:12/2/2016)... , ... December 02, 2016 , ... Yisrayl Hawkins, at ... into how this current generation fits into Bible Prophecy. Yisrayl says this generation, known ... pointing to this conclusion, showing how the details line up exactly with Bible Prophecy ...
Breaking Medicine News(10 mins):
(Date:12/2/2016)...  PipelineRx, a leading medication management technology company ... of its SaaS-based telepharmacy platform, PowerGridRx™ , ... Midyear Clinical Meeting and Exhibition, December 5-7 in ... 300 hospital clients nationally, the Company is a ... dramatically improve pharmacy operations, enhance patient safety, and ...
(Date:12/2/2016)... 2016  Maxor National Pharmacy Services, LLC ("Maxor"), today announced ... ("PSI").  The combination of Texas -based Maxor ... PSI bring together both company,s clinical expertise and high-touch patient ... industry-leading specialty pharmacy. About Maxor ... , , ...
(Date:12/2/2016)... 2, 2016 Lianluo Smart Limited (Nasdaq: ... Company") which develops, markets and sells medical devices ... China and international markets, recently attended ... Treatment New Progress Forum, co-hosted by the Institute ... , Guangdong Provincial People,s Hospital and Cardiology ...
Breaking Medicine Technology: